Effects of Incretin Pathway Elements on Bone Properties.

Autor:	Abdi AM; Laboratory of Experimental Surgery and Surgical Research 'N.S. Christeas' (LESSR), National and Kapodistrian University of Athens, Athens, GRC., Pasiou E; Department of Mechanics, National Technical University of Athens, Athens, GRC., Konstantopoulos P; Laboratory of Experimental Surgery and Surgical Research 'N.S. Christeas' (LESSR), National & Kapodistrian University of Athens, Athens, GRC., Driva TS; Laboratory of Experimental Surgery and Surgical Research 'N.S. Christeas' (LESSR), National and Kapodistrian University of Athens, Athens, GRC., Kontos A; Department of Physics, National Technical University of Athens, Athens, GRC., Papagianni E; Department of Pathology, Evangelismos General Hospital, Athens, GRC., Kourkoulis S; Department of Mechanics, National Technical University of Athens, Athens, GRC., Dimitroulis D; Laboratory of Experimental Surgery and Surgical Research 'N.S. Christeas' (LESSR), National and Kapodistrian University of Athens, Athens, GRC., Perrea DN; Laboratory of Experimental Surgery and Surgical Research 'N.S. Christeas' (LESSR), National and Kapodistrian University of Athens School of Medicine, Athens, GRC., Vlamis J; Department of Orthopedics, University of Athens, KAT Hospital, Athens, GRC.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2023 Jan 11; Vol. 15 (1), pp. e33656. Date of Electronic Publication: 2023 Jan 11 (Print Publication: 2023).
DOI:	10.7759/cureus.33656
Abstrakt:	Introduction The effects of incretin-based drugs, such as receptor agonists of glucagon-like peptide-1 and inhibitors of dipeptidyl peptidase-4, on bone metabolism are not completely clear yet. The aim of this study is to compare the effects of glucagon-like peptide-1 and inhibitors of dipeptidyl peptidase-4 on the bone to see how different elements of the incretin pathway affect bone quality in terms of biomechanical properties, bone turnover, and mineral properties. Materials and methods Forty 10-week-old Wistar rats were divided into four groups: a control group, a control diabetic group, a diabetic group treated with sitagliptin, and a diabetic group treated with exenatide. Type 2 diabetes was simulated by dietary manipulation in addition to low-dose streptozotocin, and then two different incretin-based drugs were administered. The rats were sacrificed after five weeks of therapeutic treatment. Their serum was analyzed with the enzyme-linked immunosorbent assay (ELISA) method for basic bone turnover markers, and their right femur was subjected to a three-point bending test. Finally, Hematoxylin & Eosin staining, in addition to Raman spectroscopy, were employed to access the collagen and mineral properties of the bone. Results Both incretin-based drugs reduced osteoclast function; however, they were not able to restore osteoblastic function to normal. The net effect on bone strength was surprising: bone elasticity was restored by the antidiabetic treatment, but bone strength deteriorated. Exenatide had a slightly more pronounced effect, which, although not significant, points to the direction that dipeptidyl peptidase-4 (DPP4) may be a linking factor between reduced osteoclastic function and reduced bone formation, as suggested by the literature. Conclusion DPP4 receptors seem to be one of the links between reduced osteoclast function and reduced bone remodeling, so DPP4 inhibition can be more detrimental to the bone than glucagon-like peptide-1 (GLP-1) receptor agonists. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Abdi et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu